In Bearbeitung

Bitte warten ...

Einstellungen

Einstellungen

Gehe zu Anmeldung

1. NZ560203 - Break-resistant delayed-release forms of administration

Amt
Neuseeland
Aktenzeichen/Anmeldenummer 560203
Anmeldedatum 31.07.2007
Veröffentlichungsnummer 560203
Veröffentlichungsdatum 30.09.2010
Erteilungsnummer 560203
Erteilungsdatum 08.01.2011
Veröffentlichungsart B
IPC
A61K 9/20
ASektion A Täglicher Lebensbedarf
61Medizin oder Tiermedizin; Hygiene
KZubereitungen für medizinische, zahnärztliche oder kosmetische Zwecke
9Medizinische Zubereitungen, charakterisiert durch besondere physikalische Form
20Pillen, Pastillen oder Tabletten
CPC
A61J 3/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
3Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
10into the form of compressed tablets
A61K 9/2031
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, tablets, ; discs, rods
2004Excipients; Inactive ingredients
2022Organic macromolecular compounds
2031obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
A61K 31/135
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines
135having aromatic rings ; , e.g. ketamine, nortriptyline
A61K 31/277
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
275Nitriles; Isonitriles
277having a ring, e.g. verapamil
A61K 31/4418
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
4418having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
A61K 31/4422
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
44221,4-Dihydropyridines, e.g. nifedipine, nicardipine
Anmelder Grünenthal GmbH
Erfinder Ashworth, Judy
Arkenau-Maric, Elisabeth
Bartholomaus, Johannes
Kugelmann, Heinrich
Vertreter BALDWINS INTELLECTUAL PROPERTY
Prioritätsdaten 102005005446 04.02.2005 DE
Titel
(EN) Break-resistant delayed-release forms of administration
Zusammenfassung
(EN)
Patent 560203 Disclosed is an extremely hard, mechanically stabilised, break-resistant delayed-release dosage form of administration (a break-resistant delayed-release tablet) comprising: a physiologically active substance (A); optionally one or a plurality of a physiologically compatible excipient (B); a synthetic or natural polymer (C); and optionally a natural, semi-synthetic or synthetic wax (D), wherein the form of administration has: a resistance to breaking of at least 400 N; release of at most 99% of the physiologically active substance (A) under physiological conditions after 5 hours; and neither tramadol hydrochloride nor oxycodone hydrochloride; and wherein during preparation of the form of administration: the physiologically active substance (A); the optionally one or a plurality of a physiologically compatible excipient (B); the synthetic or natural polymer (C); and the optionally natural, semi-synthetic or synthetic wax (D), are exposed to a sufficient pressure at a sufficient temperature for a sufficient period of time so that the form of administration has a resistance to breaking of at least 400 N.